Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIOCRAFT GAINS FIRST GENERIC APPROVAL FOR CINOXACIN

Executive Summary

BIOCRAFT GAINS FIRST GENERIC APPROVAL FOR CINOXACIN on Feb. 28, the first generic equivalent of Lilly subsidiary Dista's early quinolone Cinobac. Biocraft Labs received approval for 250 mg and 500 mg capsules of cinoxacin (see chart above). Since the beginning of the year, Biocraft has gained approval for four generic products. The company's generic version of Lederle's Minocin (minocycline) 50 mg and 100 mg capsules was approved on March 3. In February, in addition to cinoxacin, Biocraft received approval for baclofen 10 mg and 20 mg tablets (Ciba-Geigy's Lioresal) and metaproterenol sulfate 10 mg/5 ml syrup (Boehringer Ingelheim's Alupent). Validations for the products should be completed by April, Biocraft said. The end of February approvals were the first for Biocraft in almost two years. The company received its last ANDA approval in March 1990. Biocraft was notified as recently as mid-February by FDA that the company's responses regarding certain good manufacturing practices (GMP) violations were satisfactory. The GMP issues, which related to the manufacture of generic cephalexin at the company's Waldick, N.J. plant, were raised by the agency in an October 1989 regulatory letter. Biocraft said it has revamped its documentation system at the request of FDA. Biocraft said it has applications pending at FDA for 11 products and is planning to file ANDAs for 12 to 15 more. One of the pending applications is for Lilly's Ceclor (cefaclor), which Biocraft has said it hopes to market by the end of 1992 ("The Pink Sheet" April 22, 1991, p. 8). Lilly's patent for the top-selling antibiotic runs out in December 1992; however, Lilly has maintained that an intermediate production step patent will protect the product until December 1994. In all, FDA approved 20 ANDAs for 10 drug products and two bulk antibiotics in February. Included among the approvals are Lemmon's sulindac, Searle's theopylline extended-release 400 mg capsules, Dey Laboratories albuterol sulfate .083% inhalation solution, Novopharm's nifedipine, NMC Laboratories fluocinonide cream and Gencon's GenCept (norethindrone and ethinyl estradiol) tablets. The approval of 20 ANDAs in February is running about average with the approvals coming out of the Office of Generic Drugs in the last few months. In January, 21 ANDAs were approved. The office hit a highwater mark in December 1991, with 23 approvals in one month. As of the end of January, the generic office's backlog of applications was 650, down from 800 at the end of September ("The Pink Sheet" Oct. 14, T&G-9). The number of ANDAs over the statutory 180 day review limit had fallen from 294 to 211 by the end of January.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS020511

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel